Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Ngm Biopharmaceuticals Inc (NQ: NGM ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 4, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open - Bid (Size) 1.550 (545) Ask (Size) 1.610 (1) Prev. Close 1.540 Today's Range N/A - N/A 52wk Range 0.6002 - 2.200 Shares Outstanding 78,049,340 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News NGM Bio Announces Closing of Tender Offer April 05, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting March 19, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire Performance More News Read More NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM March 13, 2024 From Kahn Swick & Foti, LLC Via Business Wire Looking Into NGM Biopharmaceuticals's Recent Short Interest January 19, 2024 Via Benzinga Why NGM Biopharmaceuticals Stock Is Blasting Higher January 02, 2024 Via Benzinga NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results March 11, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM February 27, 2024 From Kahn Swick & Foti, LLC Via Business Wire Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 26, 2024 Via Benzinga Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday? February 26, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session February 26, 2024 Via Benzinga NGM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of NGM Biopharmaceuticals, Inc. Is Fair to Shareholders February 26, 2024 From Halper Sadeh LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), NGM Biopharmaceuticals, Inc. (Nasdaq – NGM), VIZIO Holding Corp. (NYSE - VZIO), HireRight Holdings Corporation (NYSE – HRT) February 26, 2024 From Brodsky & Smith LLC Via GlobeNewswire NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LP February 26, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in the Cowen 44th Annual Health Care Conference February 20, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference January 17, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire Why JetBlue Airways Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session January 09, 2024 Via Benzinga NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet Need January 09, 2024 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Intraday Session January 02, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session January 02, 2024 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session January 01, 2024 Via Benzinga 12 Health Care Stocks Moving In Friday's After-Market Session December 29, 2023 Via Benzinga B. Riley Securities Maintains Buy Rating for NGM Biopharmaceuticals: Here's What You Need To Know November 22, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's After-Market Session November 20, 2023 Via Benzinga NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting® November 13, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire NGM Bio to Participate in Upcoming Investor Conferences November 07, 2023 From NGM Biopharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.